ARQT

Arcutis Biotherapeutics, Inc. (ARQT) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on dermatological diseases. The company's primary revenue driver is the ZORYVE® (roflumilast) product line, which includes formulations for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. During the quarter, the company achieved net income for the first time in the reported period, driven by significant revenue growth.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 122% year-over-year in Q3 2025. Product revenue grew from $44.8M to $99.2M.
  • ZORYVE Foam: Revenue surged 146% to $49.8M, driven by the June 2025 launch for scalp/body psoriasis and Canadian expansion.
  • ZORYVE Cream 0.15%: Revenue jumped 673% to $18.9M following the July 2024 launch for atopic dermatitis.
  • ZORYVE Cream 0.3%: Revenue grew 38% to $30.5M.
• Profitability: The company reported a net income of $7.4M in Q3 2025, a significant turnaround from a net loss of $41.5M in Q3 2024. Operating income turned positive at $8.5M.
• Expense Management: Research and Development (R&D) expenses remained flat ($19.6M vs $19.5M) due to the halting of the topical JAK inhibitor program and lower preclinical costs, offset by increased spending on ZORYVE label expansions. Selling, General, and Administrative (SG&A) expenses increased 6% to $62.4M due to commercialization efforts.
• Debt Interest: Interest expense decreased 54% to $3.1M in Q3 2025 compared to $6.7M in Q3 2024, following a $100M principal paydown in October 2024 and lower interest rates.

Guidance, Outlook, and Risks

• Liquidity: The company holds $191.4M in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least 12 months. The company has $100M outstanding under its Loan Agreement with an option to re-draw up to $100M (Tranche C) subject to revenue covenants.
• Product Pipeline:
  • Submitted an sNDA in September 2025 to expand ZORYVE cream 0.3% indication to children as young as 2 years old.
  • Initiated a Phase 2 study (INTEGUMENT-INFANT) for ZORYVE cream 0.05% in infants (3 months to
  • Anticipates commencing a Phase 1 study for ARQ-234 (CD200R agonist) in Q1 2026.
  • Discontinued the ARQ-255 (topical JAK inhibitor) program for alopecia areata following Phase 1b completion.
• Risks:
  • Legal Proceedings: Patent litigation against Padagis regarding a generic ZORYVE cream was stayed in March 2025; the 30-month FDA stay on the generic approval is extended while the stay is in place. Oppositions by Teva against European patents are ongoing.
  • Regulatory/Tax: Potential impact of the "One Big Beautiful Bill Act" (signed July 2025) which includes Medicaid spending cuts that could reduce revenue.
  • Debt Covenants: The company must maintain minimum net product revenue equal to 75% of its annual plan to avoid default and access additional credit tranches.

Investor Verification Checklist

• Revenue Sustainability: Verify the trajectory of ZORYVE Foam and Cream 0.15% sales to ensure they can sustain the recent profitability trend.
• Debt Covenant Compliance: Monitor the company's ability to meet the 75% revenue covenant required to access the $100M Tranche C credit facility.
• Patent Litigation Status: Track the status of the stayed litigation with Padagis and the Teva oppositions in Europe, as these impact market exclusivity.
• Regulatory Approvals: Confirm the timeline and outcome of the sNDA for ZORYVE cream 0.3% in pediatric patients (age 2+).
• Cash Burn vs. Income: Assess whether the Q3 net income is a recurring trend or an anomaly, given the company's historical accumulated deficit of $1.16B.